Respiratory viruses, such as influenza, SARS-CoV-2 and RSV, circulate in all parts of the world and cause acute respiratory infections. Most people recover from the common symptoms, including fever, without requiring medical attention. However, respiratory viruses can cause severe illness or death, particularly among high risk groups including the very young, elderly, and those with underlying medical problems. Given the risk to vulnerable groups and the potential for respiratory viruses to cause outbreaks and epidemics, the WHO Health Emergencies Programme monitors and assesses the spread of these viruses on an ongoing basis.

Respiratory viruses surveillance in the Western Pacific Region is based on data provided by Ministries of Health and National Influenza Centers of Member States to the Global Influenza Surveillance and Response System (GISRS) online platform RespiMart and open data that Ministries of Health published on its website or shared with the WHO Regional Office for the Western Pacific. 

WHO in the Western Pacific monitors and assesses the spread of these viruses on an ongoing basis regularly publishing regional situation updates.


Featured publications

All →
Simulation exercise for influenza A(H5N1) response on access, allocation, and deployment of medical countermeasures: meeting report, Geneva, Switzerland, 4–5 September 2025, Geneva.

This document presents findings from a WHO-convened simulation exercise exploring how medical countermeasures—including vaccines, antivirals, and...

Improved influenza vaccines: full value vaccine assessment

Seasonal influenza remains a major global public health challenge, causing substantial morbidity and mortality each year. The World Health Organization...

WHO guidance on the use of licensed human influenza A(H5) vaccines for the interpandemic and emergence periods

This WHO guidance document outlines the primary objectives for the use of licensed human A(H5) vaccines for the interpandemic and emergence periods, identifies...

WHO preferred product characteristics for next generation influenza vaccines, second edition

In 2017, WHO published Preferred Product Characteristics (PPCs) to guide the development of next-generation influenza vaccines, and to encourage innovation...

Infographics

Other regional surveillance